|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 601 13th Street, NW |
Address2 | 11th Floor North |
| City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 3867-12
|
||||||||
|
6. House ID# 315600000
|
||||||||
| TYPE OF REPORT | 8. Year | 2025 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Jesse Kerns |
Date | 4/21/2025 6:08:06 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues related to drug pricing reform
-Changes to Public law 117-1769 Inflation Reduction Act
-Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act
Issues related to cardiovascular disease awareness and treatment
Issues related to FDA
Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters
Issues related to biosimilars reimbursement
Issues related to Supply Chain
Issues related to 340B
Issues related to pharmacy benefit managers
Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions.
Issues related to prohibiting the export of biotechnology to certain foreign entities (BIOCOMPETE)
Issues related to direct-to-consumer advertising
Issues related to obesity disease awareness and treatment
Issues related to biosimilars regulatory standards
Issues related to bone disease awareness and treatment
Issues related to pediatric priority review voucher reauthorization
HR 946 Optimizing Research Progress Hope and New Cures Act
HR 1492 Insuring Pathways to Innovative Cures Act
HR 1672 Maintaining Investments in New Innovation Act
HR 2214 DRUG Act
H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025
S.Con.Res.7 - An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
H.Con.Res.14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
O'Brien |
|
|
|
Helen |
Rhee |
|
|
|
Jesse |
Kerns |
|
|
|
L. Nicole |
Currie |
|
|
|
Greg |
Portner |
|
|
|
Howard |
Moon |
|
|
|
Ruth |
Hoffman |
|
|
|
Jordan |
Layson |
|
|
|
Kim |
Love |
|
|
|
Winta |
Menghis |
|
|
|
Matt |
McMurray |
|
|
|
Chad |
Pettit |
|
|
|
Chase |
Thomas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to drug pricing reform
Changes to Public law 117-1769 Inflation Reduction Act
Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act
Issues related to cardiovascular disease awareness and treatment
Issues related to reimbursement for biologics/biosimilars
Issues related to PBM reform
Issues related to obesity disease awareness and treatment
Issues related to bone disease awareness and treatment
HR 946 Optimizing Research Progress Hope and New Cures Act
HR 1492 Insuring Pathways to Innovative Cures Act
HR 1672 Maintaining Investments in New Innovation Act
H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025
S.Con.Res.7 - An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
H.Con.Res.14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
L. Nicole |
Currie |
|
|
|
Greg |
Portner |
|
|
|
Helen |
Rhee |
|
|
|
Jesse |
Kerns |
|
|
|
William |
O'Brien |
|
|
|
Howard |
Moon |
|
|
|
Ruth |
Hoffman |
|
|
|
Jordan |
Layson |
|
|
|
Kim |
Love |
|
|
|
Winta |
Menghis |
|
|
|
Matt |
McMurray |
|
|
|
Chad |
Pettit |
|
|
|
Chase |
Thomas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act
Issues related to Puerto Rico
Issues related to OECD negotiations on the taxation of global income
HR 1328 Supply Chain Security and Growth Act of 2025
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
L. Nicole |
Currie |
|
|
|
Helen |
Rhee |
|
|
|
Jordan |
Layson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Federal Trade Commission related issues, no specific bill
Issues related to the Patent Act, no specific bill
Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill
Issues related to patent thickets/product hopping
Issues related to obviousness/ double patenting
Issues related to prohibiting the export of biotechnology to certain foreign entities (BIOCOMPETE)
Issues related to FDA/PTO coordination
Issues related to skinny labeling
S.1041 A bill to amend title 35, United States Code, to address the infringement of patients that claim biological products, and for other purposes.
S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Helen |
Rhee |
|
|
|
Greg |
Portner |
|
|
|
William |
O'Brien |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAR
16. Specific lobbying issues
Issues related to tariffs
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
L. Nicole |
Currie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |